Nothing Special   »   [go: up one dir, main page]

EA202090424A1 - Бициклические ингибиторы гистондеацетилазы - Google Patents

Бициклические ингибиторы гистондеацетилазы

Info

Publication number
EA202090424A1
EA202090424A1 EA202090424A EA202090424A EA202090424A1 EA 202090424 A1 EA202090424 A1 EA 202090424A1 EA 202090424 A EA202090424 A EA 202090424A EA 202090424 A EA202090424 A EA 202090424A EA 202090424 A1 EA202090424 A1 EA 202090424A1
Authority
EA
Eurasian Patent Office
Prior art keywords
histondeacetylase
bicyclic
inhibitors
hdac2
useful
Prior art date
Application number
EA202090424A
Other languages
English (en)
Other versions
EA039417B1 (ru
Inventor
Нейтан Оливер Фуллер
Джон А. Лове III
Original Assignee
Родин Терапеутикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Родин Терапеутикс, Инк. filed Critical Родин Терапеутикс, Инк.
Publication of EA202090424A1 publication Critical patent/EA202090424A1/ru
Publication of EA039417B1 publication Critical patent/EA039417B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В настоящем изобретении предложены соединения, их фармацевтически приемлемые соли и их фармацевтические композиции, которые являются пригодными для лечения состояний, связанных с ингибированием HDAC (например, HDAC2).
EA202090424A 2017-08-07 2018-08-07 Бициклические ингибиторы гистондеацетилазы EA039417B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541807P 2017-08-07 2017-08-07
PCT/US2018/045528 WO2019032528A1 (en) 2017-08-07 2018-08-07 BICYCLIC HISTONE DEACETYLASE INHIBITORS

Publications (2)

Publication Number Publication Date
EA202090424A1 true EA202090424A1 (ru) 2020-05-26
EA039417B1 EA039417B1 (ru) 2022-01-25

Family

ID=63364199

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090424A EA039417B1 (ru) 2017-08-07 2018-08-07 Бициклические ингибиторы гистондеацетилазы

Country Status (23)

Country Link
US (2) US11225475B2 (ru)
EP (1) EP3664802B1 (ru)
JP (1) JP7152471B2 (ru)
KR (1) KR20200037286A (ru)
CN (1) CN111032040B (ru)
AU (1) AU2018313094A1 (ru)
CA (1) CA3071861A1 (ru)
DK (1) DK3664802T3 (ru)
EA (1) EA039417B1 (ru)
ES (1) ES2914355T3 (ru)
HR (1) HRP20220648T1 (ru)
HU (1) HUE058799T2 (ru)
IL (1) IL272479B2 (ru)
LT (1) LT3664802T (ru)
MA (1) MA49839B1 (ru)
MD (1) MD3664802T2 (ru)
MX (1) MX2020001484A (ru)
PL (1) PL3664802T3 (ru)
PT (1) PT3664802T (ru)
RS (1) RS63343B1 (ru)
SG (1) SG11202000970WA (ru)
SI (1) SI3664802T1 (ru)
WO (1) WO2019032528A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6936796B2 (ja) 2015-07-06 2021-09-22 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼのヘテロハロ阻害剤
DK3570834T3 (en) 2017-01-11 2022-02-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
PT3664802T (pt) 2017-08-07 2022-05-24 Alkermes Inc Inibidores bicíclicos de histona-desacetilase
US20230119479A1 (en) * 2019-12-10 2023-04-20 Shionogi & Co., Ltd. A histone deacetylase inhibitor having a nitrogen-containing aromatic heterocyclyl group

Family Cites Families (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE4212748A1 (de) 1992-04-16 1993-10-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
AU4515896A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
GB9500580D0 (en) 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
ES2151652T3 (es) 1995-02-02 2001-01-01 Smithkline Beecham Plc Derivados de indol como antagonistas del receptor 5ht.
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
US5886186A (en) 1995-10-25 1999-03-23 Versicor, Inc. Synthesis of substituted N-heteroaromatic compounds and methods of use thereof
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
EP0891361A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2763944B1 (fr) 1997-06-03 2000-12-15 Centre Nat Rech Scient Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases
JPH1149676A (ja) 1997-07-31 1999-02-23 Geron Corp ピリジン系テロメラーゼ阻害剤
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AR019190A1 (es) 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
JP2002539183A (ja) 1999-03-16 2002-11-19 サイトビア インコーポレイテッド 置換２−アミノベンズアミドカスパーゼインヒビターおよびその使用
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
AU2001286454B2 (en) 2000-08-14 2006-09-14 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
MXPA03001963A (es) 2000-09-06 2004-03-18 Johnson & Johnson Un metodo para tratar alergias usando pirazoles sustituidos.
AU2001292276A1 (en) 2000-09-27 2002-04-08 Toray Industries, Inc. Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
IL156315A0 (en) 2000-12-07 2004-01-04 Cv Therapeutics Inc Abca-1 elevating compounds
EP1353674A1 (en) 2000-12-29 2003-10-22 Alteon, Inc. Method for treating glaucoma ivb
KR100838447B1 (ko) 2001-02-21 2008-06-16 아스트라제네카 아베 헤테로폴리시클릭 화합물 및 대사향성 글루타메이트수용체 길항제로서의 그의 용도
WO2002089738A2 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
US7408067B2 (en) 2002-01-17 2008-08-05 Merck + Co., Inc. Aza-cyclic compounds as modulators of acetylcholine receptors
JP4167848B2 (ja) 2002-04-10 2008-10-22 広栄化学工業株式会社 ビアリール化合物の製造法
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
WO2004000820A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
CA2515544A1 (en) 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
DK1648879T3 (da) 2003-07-24 2009-02-23 Euro Celtique Sa Heteroaryl-tetrahydropyridyl-forbindelser, der er anvendelige til behandling eller forebyggelse af smerte
TWI287567B (en) 2003-07-30 2007-10-01 Chi Mei Optoelectronics Corp Light-emitting element and iridium complex
US20050049241A1 (en) 2003-08-08 2005-03-03 Carruthers Nicholas I. Pyridyl piperazinyl ureas
MXPA06001739A (es) 2003-08-14 2006-05-12 Asahi Kasei Pharma Corp Derivado de acido arilalcanoico substituido y uso del mismo.
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
CA2539117A1 (en) 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
US20070149547A1 (en) 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
EP1732919A1 (en) 2004-03-30 2006-12-20 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
SI1735278T1 (sl) 2004-04-01 2010-05-31 Lilly Co Eli Agenti histamin h receptorja priprava in terapevtska uporaba
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
CA2575081C (en) 2004-07-26 2013-05-07 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
JP2008516989A (ja) 2004-10-19 2008-05-22 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー 組成物及び抗腫瘍剤としてのその使用
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
JP2008520741A (ja) 2004-11-23 2008-06-19 ピーティーシー セラピューティクス， インコーポレイテッド 翻訳制御によるｖｅｇｆ生成を阻害するための活性因子としてのテトラヒドロカルバゾール
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
JP2008525406A (ja) 2004-12-22 2008-07-17 アストラゼネカ アクチボラグ 抗がん剤として使用するためのピリジンカルボキサミド誘導体
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
AU2006204750C1 (en) 2005-01-14 2012-11-01 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
EP1683796A1 (en) 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
EP1879548A2 (en) 2005-05-13 2008-01-23 Ciba Specialty Chemicals Holding Inc. Process for coloring keratin fibers comprising metal complexes
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
EP1890694A4 (en) 2005-06-02 2010-10-27 Bayer Cropscience Ag SUBSTITUTED PHENYLALKYL HETEROARYL DERIVATIVES
JP2008543754A (ja) 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
AR053901A1 (es) 2005-06-20 2007-05-23 Astrazeneca Ab Formas fisicas de oxabispidinas n,n'- disustituidas
US7456195B2 (en) 2005-06-24 2008-11-25 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
FR2892412B1 (fr) 2005-10-26 2008-05-16 Galderma Res & Dev Composes biaromatiques modulateurs des ppars
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
JP2009514858A (ja) 2005-11-03 2009-04-09 メルク エンド カムパニー インコーポレーテッド アリール−ピラゾリルモチーフを有するヒストンデアセチラーゼ阻害剤
SI2774925T1 (sl) 2005-11-08 2017-04-26 Vertex Pharmaceuticals Incorporated Heterociklični modulatorji prenašalcev z ATP-vezavno kaseto
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
BRPI0619252A2 (pt) 2005-11-30 2011-09-20 Vertex Pharma inibidores de c-met e seus usos
ES2397401T3 (es) 2005-12-23 2013-03-06 F. Hoffmann-La Roche Ag Derivados de aril-isoxazol-4-il-oxadiazol
AU2007208494A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Fluorinated arylamide derivatives
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
JP2007283748A (ja) 2006-03-23 2007-11-01 Fujifilm Corp 光記録媒体および可視情報記録方法
EP2368550B1 (en) 2006-03-27 2013-09-04 The Regents of the University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8598168B2 (en) 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
JPWO2007125984A1 (ja) 2006-04-28 2009-09-10 日本農薬株式会社 イソキサゾリン誘導体及び有害生物防除剤並びにその使用方法
WO2007129044A1 (en) 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
EP2016068A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Pyrazole derivatives and their use as pi3k inhibitors
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
ATE465164T1 (de) 2006-05-31 2010-05-15 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2007143557A2 (en) 2006-06-02 2007-12-13 Brandeis University Compounds and methods for treating mammalian gastrointestinal parasitic infections
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
ES2431466T3 (es) 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2049124A4 (en) 2006-07-20 2010-02-10 Merck & Co Inc PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
KR20090029274A (ko) 2006-07-21 2009-03-20 아이알엠 엘엘씨 Ｉｔｐｋｂ 억제제로서의 화합물 및 조성물
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US9102622B2 (en) 2006-07-28 2015-08-11 University Of Connecticut Fatty acid amide hydrolase inhibitors
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
US20080076813A1 (en) 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
AU2007297754B2 (en) 2006-09-18 2012-05-17 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-MET and uses thereof
AU2007311591B2 (en) 2006-10-18 2010-10-07 Pfizer Products Inc. Biaryl ether urea compounds
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
WO2008053913A1 (fr) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
US20080145816A1 (en) 2006-12-15 2008-06-19 Hershey Adrienne A Yankauer suction device
ES2527696T3 (es) 2006-12-21 2015-01-28 Nerviano Medical Sciences S.R.L. Derivados de pirazoloquinazolina sustituidos, procedimientos para su preparación y su uso como inhibidores de la quinasa
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
AR064660A1 (es) 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
JP2008179068A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
JP2008179067A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
ES2702362T3 (es) 2007-01-31 2019-02-28 Ym Biosciences Australia Pty Compuestos a base de tiopirimidina y usos de los mismos
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
MX2009009936A (es) 2007-03-20 2010-02-11 Curis Inc Amino piridina fusionada como inhibidores de hsp90.
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
JP2010524913A (ja) 2007-04-20 2010-07-22 バイオリポックス アーベー 炎症治療において有用なピラゾール
WO2008139152A1 (en) 2007-05-11 2008-11-20 Sentinel Oncology Limited N-oxide-containing pharmaceutical compounds
NZ581817A (en) 2007-06-03 2012-05-25 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
WO2008151211A1 (en) 2007-06-05 2008-12-11 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009005638A2 (en) 2007-06-27 2009-01-08 Merck & Co., Inc. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
UY31281A1 (es) 2007-08-13 2009-03-31 Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
ES2535166T3 (es) 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
US8354383B2 (en) 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
NZ584279A (en) 2007-09-19 2011-11-25 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
JP5469604B2 (ja) 2007-09-19 2014-04-16 ４エスツェー アクチェンゲゼルシャフト 新規テトラヒドロ融合ピリジン
WO2009052320A1 (en) 2007-10-16 2009-04-23 Northeastern University Methods and compounds for modulating cannabinoid activity
US20090156825A1 (en) 2007-11-26 2009-06-18 Heidebrecht Jr Richard W Fluorescent compounds that bind to histone deacetylase
WO2009078992A1 (en) 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
EP2244709A4 (en) 2008-02-07 2012-02-29 Synta Pharmaceuticals Corp TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009152087A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
CA2727389A1 (en) 2008-06-10 2009-12-17 Prabha N. Ibrahim 5h-pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
KR20110026481A (ko) 2008-06-20 2011-03-15 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１１９ 작동약 및 이의 용도
CA2729327C (en) 2008-06-27 2016-10-11 Xenon Pharmaceuticals Inc. Heterocyclic derivatives that modulate the activity of stearoyl-coa desaturase
JP5309216B2 (ja) 2008-07-11 2013-10-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての４−フェノキシメチルピペリジン類
WO2010007756A1 (ja) 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
EP2380631A1 (en) 2008-07-15 2011-10-26 Novartis AG Heteroaryl derivatives as DGAT1 inhibitors
JP5524215B2 (ja) 2008-09-19 2014-06-18 ファイザー・インク 抗菌剤として有用なヒドロキサム酸誘導体
EP2350052B1 (en) 2008-09-29 2014-08-13 Boehringer Ingelheim International GmbH Antiproliferative compounds
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
WO2010088574A1 (en) 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles and related analogs as sirtuin modulators
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
WO2010108921A1 (en) 2009-03-27 2010-09-30 Nerviano Medical Sciences S.R.L. N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors
US20120010135A1 (en) 2009-04-01 2012-01-12 Xenon Pharmaceuticals Inc. Spiro derivatives for the modulation of stearoyl-coa desaturase
WO2010127855A1 (en) 2009-05-07 2010-11-11 Grünenthal GmbH Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
JP2011006408A (ja) 2009-05-29 2011-01-13 Sumitomo Chemical Co Ltd 神経栄養因子の活性が関与する疾患の治療または予防剤
BRPI1010884A2 (pt) 2009-06-08 2016-03-15 Gilead Sciences Inc composto inibidores hdac de alcanoilamino benzamida anilina
WO2010151747A1 (en) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimine compounds and methods of making and using same
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2011072275A2 (en) 2009-12-11 2011-06-16 Nono, Inc. Agents and methods for treating ischemic and other diseases
WO2011073328A1 (en) 2009-12-16 2011-06-23 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
CA2794018C (en) 2010-03-24 2016-05-10 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
US8703959B2 (en) 2010-04-06 2014-04-22 Nippon Soda Co., Ltd Nitrogen-containing heterocyclic compound and method for producing same
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
EP2588465B1 (en) 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2012004217A1 (en) 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2606056A4 (en) 2010-08-20 2014-01-08 Harvard College HIGH QUALITY PALLADIUM FLUORIDE COMPLEXES AND ITS USES
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
CA2817319A1 (en) 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Triazole derivatives as sgc stimulators
WO2012074050A1 (ja) 2010-12-01 2012-06-07 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板、液晶表示装置、及び化合物
JP5992435B2 (ja) 2010-12-21 2016-09-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 循環からの生体分子の除去剤
WO2012085650A1 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US20130303507A1 (en) 2011-01-28 2013-11-14 Novartis Ag Substituted hetero-biaryl compounds and their uses
US8957066B2 (en) * 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012117097A1 (en) 2011-03-03 2012-09-07 Universität des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
SG193331A1 (en) 2011-03-18 2013-10-30 Lupin Ltd Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
EP2712655B1 (en) 2011-04-28 2019-12-18 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9421274B2 (en) 2011-05-16 2016-08-23 Koninklijke Philips N.V. Bio-orthogonal drug activation
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
MX2014000964A (es) 2011-07-26 2014-03-27 Gruenenthal Gmbh Derivados aza heterociclicos sustituidos.
JP2014521616A (ja) 2011-07-26 2014-08-28 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換ヘテロ芳香族ピラゾール含有カルボキサミドおよび尿素誘導体
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
BR112014003112A2 (pt) 2011-08-12 2017-02-21 Basf Se composto da fórmula geral (i), métodos para preparar um composto da fórmula (i), composição agrícola ou veterinária, método para combater ou controlar pragas invertebradas, método para proteger o cultivo de plantas, método para a proteção de sementes, semente, usos de um composto e método para tratar um animal
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013041602A1 (de) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Verwendung 4-substituierter 1-phenyl-pyrazol-3-carbonsäurederivate als wirkstoffe gegen abiotischen pflanzenstress
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
WO2013059648A1 (en) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013152198A1 (en) 2012-04-04 2013-10-10 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
DE112013001975T5 (de) 2012-04-12 2015-01-15 The University Of Hong Kong Platin(II)-Komplexe für OLED-Anwendungen
WO2013163404A1 (en) 2012-04-27 2013-10-31 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
EP2857396B1 (en) 2012-05-31 2018-11-21 Sumitomo Chemical Co., Ltd Fused heterocyclic compounds for pest control
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
MX2014015156A (es) 2012-06-12 2015-08-06 Abbvie Inc Derivados de piridinona y piridazinona.
JP2015521603A (ja) 2012-06-15 2015-07-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 脳癌の新規治療薬
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
US9682970B2 (en) 2012-06-29 2017-06-20 Biotium, Inc. Fluorescent compounds and uses thereof
RU2696278C2 (ru) 2012-07-18 2019-08-01 Юниверсити Оф Нотр Дам Дю Лак 5,5-гетероароматические противоинфекционные соединения
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014025808A1 (en) 2012-08-06 2014-02-13 The General Hospital Corporation Curcumin analogs
EP2888256A4 (en) 2012-08-24 2016-02-17 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9145433B2 (en) 2012-10-05 2015-09-29 Rigel Pharmaceuticals, Inc. GDF-8 inhibitors
AU2013329832A1 (en) 2012-10-11 2015-05-28 Grunenthal Gmbh Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
JP2014101353A (ja) 2012-10-26 2014-06-05 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
CA2889892A1 (en) 2012-11-09 2014-05-15 Indiana University Research And Technology Corporation Alternative uses for hbv assembly effectors
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
US10927139B2 (en) 2012-11-22 2021-02-23 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081301A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014089112A1 (en) 2012-12-04 2014-06-12 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
CN103864754B (zh) 2012-12-10 2016-12-21 中国科学院上海药物研究所 五元唑类杂环化合物及其制备方法、药物组合物和用途
JP6511430B2 (ja) 2013-03-11 2019-05-15 ザ・ブロード・インスティテュート・インコーポレイテッド がんの治療のための化合物および組成物
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
SG11201507070XA (en) 2013-03-15 2015-10-29 Epizyme Inc Carm1 inhibitors and uses thereof
EA201591137A1 (ru) 2013-03-15 2016-02-29 Селджен Авиломикс Рисерч, Инк. Ингибиторы mk2 и их применения
JP6235048B2 (ja) 2013-03-20 2017-11-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 尿素誘導体及びその脂肪酸結合タンパク質（ｆａｂｐ）阻害剤としての使用
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104163792B (zh) 2013-05-20 2017-04-12 湖南化工研究院 N‑吡啶酰胺类化合物及其制备方法与应用
CN104163791B (zh) 2013-05-20 2017-05-03 湖南化工研究院 N‑吡啶（杂）芳酰胺类化合物及其制备方法与应用
EP3004083A4 (en) 2013-05-24 2016-11-16 California Inst Biomedical Res COMPOUNDS FOR THE TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
CN111423479A (zh) 2013-05-30 2020-07-17 华盛顿大学 用于治疗细菌性感染的化合物和方法
US9673409B2 (en) 2013-06-10 2017-06-06 Arizona Board Of Regents On Behalf Of Arizona State University Phosphorescent tetradentate metal complexes having modified emission spectra
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
GB2516303A (en) 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
WO2015031725A1 (en) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Transition metal-catalyzed imidation of arenes
EA201690230A1 (ru) 2013-09-06 2016-07-29 Инсепшн 2, Инк. Соединения триазолона и их применения
US9663508B2 (en) 2013-10-01 2017-05-30 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
CN114380700A (zh) 2013-10-08 2022-04-22 卢庆彬 用于靶向化疗的非铂基抗癌化合物
AU2014340318B2 (en) 2013-10-21 2019-01-17 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
AU2014353150A1 (en) 2013-11-19 2016-07-07 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
CN103601718A (zh) 2013-12-05 2014-02-26 江西天人生态股份有限公司 一类基于鱼泥丁受体的邻甲酰氨基苯甲酰胺衍生物及其制备方法和用途
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
CN103804312B (zh) 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
WO2015142903A2 (en) 2014-03-17 2015-09-24 Genentech, Inc. Method of controlling lactate production with piperdine-dione derivatives
GB201405002D0 (en) 2014-03-20 2014-05-07 Isis Innovation Fluorination method
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
WO2015157057A1 (en) 2014-04-09 2015-10-15 Lumiphore, Inc Macrocycles
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
CA2951026A1 (en) * 2014-06-02 2015-12-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2016018795A1 (en) 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
US9969744B2 (en) 2014-08-04 2018-05-15 Fundación La Investigación Médica Aplicada Compounds for use in cognition improvement
JP6625638B2 (ja) 2014-08-18 2019-12-25 ハドソン・バイオファーマ・インコーポレイテッド Ｍｄｍ２阻害薬としてのスピロピロリジン
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
US20160137630A1 (en) 2014-10-08 2016-05-19 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2016100711A1 (en) 2014-12-18 2016-06-23 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
ES2928084T3 (es) 2015-02-20 2022-11-15 Rigel Pharmaceuticals Inc Inhibidores de GDF-8
WO2016173557A1 (zh) 2015-04-30 2016-11-03 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
WO2016176657A1 (en) 2015-04-30 2016-11-03 Memorial Sloan-Kettering Cancer Center Mitragynine analogs and uses thereof
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
JP6936796B2 (ja) 2015-07-06 2021-09-22 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼのヘテロハロ阻害剤
WO2017027984A1 (en) 2015-08-20 2017-02-23 Simon Fraser University Compounds and methods for treatment of cancer by inhibiting atg4b and blocking autophagy
US10980755B2 (en) 2015-09-10 2021-04-20 The Regents Of The University Of California LRH-1 modulators
EP3362436B1 (en) 2015-09-14 2021-06-30 Universiteit Antwerpen Process for the catalytic directed cleavage of amide-containing compounds
WO2017075694A1 (en) 2015-11-04 2017-05-11 Simon Fraser University Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
MX2018010176A (es) 2016-02-23 2019-01-21 Taiho Pharmaceutical Co Ltd Compuesto novedoso de pirimidina condensada o sal del mismo.
DK3426654T3 (en) 2016-03-09 2022-01-03 Harvard College Direct palladium-catalyzed aromatic fluorination
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
AU2017363268A1 (en) 2016-11-23 2019-05-30 Regenacy Pharmaceuticals, Llc Piperazine derivatives as selective HDAC1,2 inhibitors
DK3570834T3 (en) 2017-01-11 2022-02-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
CN106946890A (zh) 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
PT3664802T (pt) 2017-08-07 2022-05-24 Alkermes Inc Inibidores bicíclicos de histona-desacetilase
CN112424184A (zh) 2018-07-13 2021-02-26 奥克梅斯公司 组蛋白脱乙酰酶双环抑制剂
SG11202012918PA (en) 2018-07-13 2021-02-25 Alkermes Inc Bicyclic inhibitors of histone deacetylase

Also Published As

Publication number Publication date
PL3664802T3 (pl) 2022-07-11
CN111032040B (zh) 2023-08-29
MX2020001484A (es) 2020-08-20
SG11202000970WA (en) 2020-02-27
LT3664802T (lt) 2022-06-27
MA49839B1 (fr) 2022-05-31
RS63343B1 (sr) 2022-07-29
HUE058799T2 (hu) 2022-09-28
KR20200037286A (ko) 2020-04-08
JP7152471B2 (ja) 2022-10-12
IL272479A (en) 2020-03-31
US20210147410A1 (en) 2021-05-20
MD3664802T2 (ro) 2022-07-31
SI3664802T1 (sl) 2022-10-28
US11225475B2 (en) 2022-01-18
EP3664802A1 (en) 2020-06-17
US20220340558A1 (en) 2022-10-27
IL272479B1 (en) 2023-04-01
PT3664802T (pt) 2022-05-24
CA3071861A1 (en) 2019-02-14
HRP20220648T1 (hr) 2022-09-02
WO2019032528A8 (en) 2019-03-21
CN111032040A (zh) 2020-04-17
IL272479B2 (en) 2023-08-01
AU2018313094A1 (en) 2020-02-20
WO2019032528A1 (en) 2019-02-14
EP3664802B1 (en) 2022-02-23
ES2914355T3 (es) 2022-06-09
EA039417B1 (ru) 2022-01-25
DK3664802T3 (en) 2022-05-30
JP2020530019A (ja) 2020-10-15
MA49839A (fr) 2020-06-17
US11912702B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
GEP20237506B (en) Pcsk9 antagonist compounds
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MX2019008302A (es) Inhibidores biciclicos de histona desacetilasa.
EA201691421A1 (ru) Гетероарилы и их применение
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2023002507A (es) Inhibidores de cd73.
CR20200545A (es) Inhibidores magl
EA201792255A1 (ru) Ингибиторы деацетилаз гистонов и композиции и способы их применения
PH12019501097A1 (en) Magl inhibitors
EA201991700A1 (ru) Селективные ингибиторы jak1
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
PH12019501102A1 (en) Magl inhibitors
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
EA202190070A1 (ru) Бициклические ингибиторы гистондеацетилазы
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
EA201792247A1 (ru) Ингибиторы деацетилаз гистонов и композиции и способы их применения
EA202190077A1 (ru) Ингибиторы гистондеацетилазы
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EA201792676A1 (ru) Ингибиторы jak1
EA202090843A1 (ru) Соединения ингибиторы btk
EA201791839A1 (ru) Диметоксифенильные ингибиторы везикулярного транспортера моноаминов 2